Article metrics
Other content recommended for you
- When to start paediatric testing of the adult HIV cure research agenda?
- Why cure, why now?
- Reconceptualising risk–benefit analyses: the case of HIV cure research
- First-in-human HIV-remission studies: reducing and justifying risk
- The Ebola clinical trials: a precedent for research ethics in disasters
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- How to keep high-risk studies ethical: classifying candidate solutions
- Cancer immunotherapy in adult patients with HIV
- Factors associated with attitudes towards HIV cure research among transgender women and travestis: a cross-sectional survey in São Paulo, Brazil
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia